BBDF Wins FDA New Drug Approval to Pursue Clinical Trials

Beyond Batten Disease Foundation 101 Wins FDA Investigational New Drug Approval to Pursue Clinical Trials

SAM is excited to announce that the Beyond Batten Disease Foundation reached an incredible milestone in rare disease drug development: FDA approval to launch a Phase I/II clinical trial. We are honored and grateful to manage and support an organization making a difference in the lives of families affected by juvenile Batten disease. Led by SAM Account Executive Mary Beth Kiser, who serves as BBDF President and CEO, our team is excited to celebrate the result of hard work, sustained effort, and hope over the last 13 years and are proud to play a part in this success. Read more at https://bit.ly/33Q17Nc 

Share this post:

Comments on "BBDF Wins FDA New Drug Approval to Pursue Clinical Trials"

Comments 0-5 of 0

Please login to comment